Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.20p -2.03% 9.65p 894,692 14:54:08
Bid Price Offer Price High Price Low Price Open Price
9.50p 9.80p 9.85p 9.55p 9.85p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.93 -1.26 8.8

N4 Pharma (N4P) Latest News

More N4 Pharma News
N4 Pharma Takeover Rumours

N4 Pharma (N4P) Share Charts

1 Year N4 Pharma Chart

1 Year N4 Pharma Chart

1 Month N4 Pharma Chart

1 Month N4 Pharma Chart

Intraday N4 Pharma Chart

Intraday N4 Pharma Chart

N4 Pharma (N4P) Discussions and Chat

N4 Pharma Forums and Chat

Date Time Title Posts
17/7/201814:17N4 Pharma261
11/7/201822:32N4 Pharma - Making good drugs better.3,883

Add a New Thread

N4 Pharma (N4P) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-07-18 16:09:129.6575,0007,237.50O
2018-07-18 14:39:359.755,007488.03O
2018-07-18 13:51:409.5835,2033,370.69O
2018-07-18 12:25:549.905,000495.00O
2018-07-18 12:22:299.9015,0001,485.00O
View all N4 Pharma trades in real-time

N4 Pharma (N4P) Top Chat Posts

DateSubject
18/7/2018
09:20
N4 Pharma Daily Update: N4 Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 9.85p.
N4 Pharma has a 4 week average price of 9.10p and a 12 week average price of 9.10p.
The 1 year high share price is 35.50p while the 1 year low share price is currently 4.75p.
There are currently 90,962,537 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of N4 Pharma is £8,777,884.82.
14/7/2018
14:36
hughwilson: If my memory serves me correctly, that poster was at the time, bragging that the warrants were almost exhausted. The reality was that there was still over 15 million or way over half the warrants left. At the time the continuing issue of warrants was suppressing the share price, so a poster suggesting that the warrants were at an end is at best deception based on them not knowing what they were talking about OR if they did then an outright lie. Any person who states something as fact to a sensitive market should have done their sums first. The intention was to give the impression that that which was suppressing the share price was at an end which at the time was most certainly not. Very easy to say when you get caught out that you made a mistake but we can all add up and if that poster was unsure of how many warrants were left then he should not have posted in such a certain manner that they were ended.
10/7/2018
21:18
dplewis1: Well my twisted mind saw the comment in parentheses ("which is not expected"), which changes the whole emphasis of the post. The overarching direction of your posting is to ignore the risks and overstate the upside. I don't need to provide evidence as it's there for all to see but a couple of examples might be:"Something is moving the price and that something is getting closer." Nice little unsubstantiated post to insinuate that a background 'in the know' buyer was accumulating. "The probability is that Nuvec is going to be huge." "Today marks the 8 week mark. Within the next two weeks the results of the Sildenafil trials will be out, not for me or Jo public but for someone in the know so the news will be in the share price long before they are announced. We have already seen steady large buys for the last few weeks trying to build a share without attracting attention..""That does not alter the argument for N4 at all. Their product is superior to the generics and will command a higher price and is fully patented. If Pfizer do not go down the JV route with N4 then from the time N4`s product hits the market they will be losing market share.""No matter how much Pfizer advertise their product, it is just a generic and no better than any other generic. N4`s sildenafil will be better performing and fully patented. Pfizer would be stupid not to do a JV."Those are just a few. It is not just my twisted mind that interprets that language as hugely overconfident in its nature.
16/6/2018
12:03
parob: Due to the recent rise and huge potential that N4 has, there's a lot of NEW interest in this stock and imo momentum alone could drive the price to new highs soon. Here are some POTENTIAL share price catalysts:- Further collaborations on Nuvec.- Nuvec licensing deal with MedImmune/AZ.- Commercial tie up for duloxetine reformulation.- Positive human trial results for Sildenafil - announcement due in Aug.- Broker upgrade to share price target.- Being tipped in the media/tipster websites.- Further holdings RNS/Institutional buying.- News on other patents.- News on other drugs being reformulated.- News on further grants.- Media coverage of any news listed above.
16/6/2018
11:12
hughwilson: Ch1rp, If N4 achieves its aims then the share price will be multiples of the share price today. The AimChaos report gave N4 a fair valuation of 95p at present. In that report he stresses throughout that his valuation is cautious and yet the potential is huge. That is why we have a potential £400m company valued at £25m.
13/6/2018
13:25
hughwilson: Today marks the 8 week mark. Within the next two weeks the results of the Sildenafil trials will be out, not for me or Jo public but for someone in the know so the news will be in the share price long before they are announced. We have already seen steady large buys for the last few weeks trying to build a share without attracting attention but if you see the share price really taking off over the next two weeks then you will know that you will be looking at good trial results.
24/2/2018
09:54
parob: As we know N4P have two potential ‘game changers’ at the moment (there could be more in the future): Sildenafil and Nuvec. We just need one of these to be a success and we’re looking at a share price in the pounds IMO. If both are a success I wouldn’t want to hazard a guess at where the share price could end up. At this stage, everything is going to plan and I know I keep harping on about it but the AZ collaboration was even ahead of the company’s anticipated schedule. Hugh, this article you posted yesterday was a great find and definitely worth a read: hTTps://www.streetwisereports.com/article/2017/02/01/companies-flocking-to-japan-for-biotech-deals.html
07/2/2018
22:53
hughwilson: "Quote me one thing that is "negative dribble" - Delays / problems with their products - No deal announcements Bad results from either will see the share price hammered You are all deluded if you think N4P is somehow special and will be immune to a general market sell off Keep telling the punters to hold/buy so you guys can exit? Well lads, this has spoiled your fun Well there is six for you. If you think this share could be three times its share price based on one product then you have no reason to spout such negativity. I note you don`t post when the share is rising , only when you think it may be due a correction.
03/2/2018
08:53
nick2412: Hugh, I guess the wording translates as MedImmune / AZ have the right to discuss and seek exclusivity whilst N4P retain the right to name their price. I think it would require a very large initial milestone payment for an exclusive license, or, alternatively, necessitate buying Nuvac outright for a sum that equates in the N4P share price to pounds rather than pence for AZ (or any other company for that matter) to achieve exclusivity. The studiy highlighting the differences between Nuvac and current / other DNA /RNA drug delivery methods should be published this quarter and perhaps before the Japan visit. Existing findings suggest that Nuvac will be in demand so the potential is a)a lucrative exclusive deal with AZ b) multiple licensing deals with different partners c) a bidding war to buy Nuvac outright. Early days but it's looking interesting to say the least.
03/7/2017
18:23
bdog51: I'm with you on that Flash. When the direction of travel reverses, the N4P share price can really motor. Bargain price down at these low levels right now. Just takes a bit of news flow to change the tide.
18/5/2017
12:50
someuwin: CEO owns 17% of the equity here. This is almost entirely from his own purchases on the market when this was ONZ (see repeated Holdings RNSs last year). Furthermore his consideration shares resulting from the new N4P listing are deferred until the N4P share price has been over 15p for 10 consecutive days. ...I don't think it will be too long before that situation occurs.
N4 Pharma share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180719 00:04:01